<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450449</url>
  </required_header>
  <id_info>
    <org_study_id>E33033</org_study_id>
    <nct_id>NCT01450449</nct_id>
  </id_info>
  <brief_title>Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme</brief_title>
  <official_title>A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Atomic Energy Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Escuela de Medicina Nuclear</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>N.N. Alexandrov National Cancer Centre of Belarus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital A.C. Camargo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Radiomedicina (IRAM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Cipto Mangunkusumo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Salah Azaïz Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wilson Roa Professional Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>High Technology Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Atomic Energy Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre prospective, non-inferiority trial. Patients will be randomized to two
      treatment groups in a 1:1 ratio and will be stratified by age, Karnofsky Performance Status
      and extent of the surgical resection.

      This study will assess the effect of a one-week radiotherapy regimen in comparison with a
      three-week radiotherapy regimen on the survival of elderly and/or frail patients with
      glioblastoma multiforme (Frail: ≥&gt;50 years old and with a KPS of 50% or less50%-70%; Elderly
      and frail: ≥65 years and with a KPS of 50% - 70%; Elderly: ≥65 years and with a KPS of 80% -
      100%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre prospective, non-inferiority trial. Patients will be randomized to two
      treatment groups in a 1:1 ratio and will be stratified by:

        -  Age (&lt;65 and ≥65 years old)

        -  Karnofsky Performance Status (≤70 and &gt; 7050 or higher)

        -  Extent of the resection at surgery (biopsy only versus complete/near total and gross
           total or incomplete /partial resection)

      Randomization:

      Patients will be randomized to receive one of the two following treatments:

      Arm 1:

        -  Short Radiotherapy

        -  25 Gy/5 fractions

        -  1 week (5 fractions per week)

      Arm 2:

        -  Regular Radiotherapy

        -  40 Gy/15 fractions

        -  3 weeks (5 fractions per week)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2.5 years</time_frame>
    <description>The time from randomization to the time of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2.5 years</time_frame>
    <description>2.5 years including six months of follow-up after initial accrual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2.5 years</time_frame>
    <description>Quality of life will be assessed prior to study randomization and 4 weeks following completion of radiotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Short Course Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short Course</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Standard Course Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Course</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>25 Gy in 5 daily fractions over 1 week</description>
    <arm_group_label>Arm 1 - Short Course Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>40 Gy in 15 daily fractions over 3 weeks</description>
    <arm_group_label>Arm 2 - Standard Course Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically confirmed newly diagnosed glioblastoma multiforme (GBM, WHO grade
             IV). The histological diagnosis must have been made locally after biopsy or
             neurosurgical tumour resection.

          -  Initial surgery/biopsy at diagnosis performed &lt; 6 weeks (42 days) prior to
             randomization.

          -  Patient's age is 50 years or older.

          -  Karnofsky performance status is 50% or higher.

          -  Patients may have received and continue to receive corticosteroids, but they have to
             be on a stable or decreasing dose for at least 14 days prior to randomization.

          -  Patients must not have received prior chemotherapy or radiotherapy.

          -  Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life
             questionnaires in either English or any other language the questionnaire is officially
             translated into. The baseline assessment (prior to start of radiotherapy) must already
             have been completed. Inability (illiteracy, loss of sight, or other equivalent reason)
             to complete the questionnaires will not make the patient ineligible for the study. In
             centres where patients are not able to read or write, proxy interviews will be
             conducted in-person or via telephone by the nurse at that particular centre.

          -  Patient consent must be obtained according to local institutional policy. It will be
             the responsibility of the local participating investigators to obtain the necessary
             local clearance, and to indicate in writing to the IAEA Study Coordinator that such
             clearance has been obtained, before the trial can commence in that centre. A copy of
             the initial full board ERB approval and approved consent form must be sent to the
             Project Officer at IAEA. The patient must sign the consent form prior to randomization
             or registration.

          -  Patients must be accessible for treatment and follow-up. Investigators must assure
             themselves the patients randomized on this trial will be available for complete
             documentation of the treatment, adverse events, and follow-up.

          -  Protocol treatment is to begin within 2 weeks of patient randomization.

        Exclusion Criteria:

          -  Patients with a history of other malignancies, except: adequately treated non-melanoma
             skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for 3 or more years.

          -  Patients with a serious active infection or other serious underlying medical
             conditions that would impair the ability of the patient to receive protocol treatment
             or comply with protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Fidarova</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Atomic Energy Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion Escuela de Medicina Nuclear</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N. Alexandrov National Cancer Centre of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>223040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade de Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90050-70</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;A.C. Camargo&quot;, Fundacao &quot;Antonio Prudente&quot;</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilson Roa Professional Corporation</name>
      <address>
        <city>Edmonton</city>
        <zip>Alberta T6R 2A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Radiomedicina (IRAM)</name>
      <address>
        <city>Santiago</city>
        <zip>6671407</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaalhailga</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Technology Medical Center, University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education and Research (PGIMER)</name>
      <address>
        <city>Chandigarh</city>
        <zip>160 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cipto Magunkusumo General Hospital, University of Indonesia</name>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICORG The All Ireland Cooperative Oncology</name>
      <address>
        <city>Dublin</city>
        <zip>2</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marie Curie- Sklodowska Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut National de Cancer Salah Aziz, Ministere de la Sante Publique</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Hospital</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Ireland</country>
    <country>Poland</country>
    <country>Thailand</country>
    <country>Tunisia</country>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Newall J, Ransohoff J, Kaplan B. Glioblastoma in the older patient: how long a course of radiotherapy is necessary? J Neurooncol. 1988 Dec;6(4):325-7.</citation>
    <PMID>2851647</PMID>
  </reference>
  <reference>
    <citation>Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):835-9.</citation>
    <PMID>8040031</PMID>
  </reference>
  <reference>
    <citation>Kleinberg L, Slick T, Enger C, Grossman S, Brem H, Wharam MD Jr. Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):31-6.</citation>
    <PMID>9212001</PMID>
  </reference>
  <reference>
    <citation>Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J. Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study. J Neurooncol. 1999 Aug;44(1):85-90.</citation>
    <PMID>10582674</PMID>
  </reference>
  <reference>
    <citation>Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004 May 1;22(9):1583-8. Epub 2004 Mar 29.</citation>
    <PMID>15051755</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBM, fractionation, short course, standard course</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

